67 filings
Page 2 of 4
8-K
4v1rh sj9tkzh0giv93
8 Nov 22
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
7:07am
8-K
10ut6ohho1my94
3 Nov 22
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:08am
8-K
pkkg 1yqoz2m97mjnq5
7 Sep 22
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
7:03am
8-K
kbc d0g3h
4 Aug 22
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:03am
8-K
b9vwp8jncix4
15 Jul 22
Entry into a Material Definitive Agreement
5:22pm
8-K
mlw7lj
12 Jul 22
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
4:00pm
8-K
522cd
27 Jun 22
Submission of Matters to a Vote of Security Holders
4:10pm
8-K
1d3kuu05wj 2u
5 May 22
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:06am
8-K
bzugfy5i7hmocs
12 Apr 22
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
4:14pm
8-K
kaf j449f6
1 Mar 22
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
7:00am
8-K
onldpzak kc0lfbe
5 Jan 22
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
7:14am
8-K
j03tkmnp9gauiy7
8 Nov 21
Regulation FD Disclosure
5:02pm
8-K
h81rz
4 Nov 21
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
vvxr8b2
26 Oct 21
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
8:58am
8-K
nbv95
14 Oct 21
Entry into a Material Definitive Agreement
12:00am
8-K
ev1zajmmjbp abpk6h0
7 Oct 21
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
4:14pm
8-K
0d9ki12e6 htxcd3mw5x
5 Aug 21
Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
oq5 kpwq8s55
13 Jul 21
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
7:54am
8-K
nh59bukfm1ry96qrja
28 Jun 21
Submission of Matters to a Vote of Security Holders
4:43pm
8-K
c3d9iz1
24 May 21
Other Events
4:35pm